[U.S. Stocks Movement] Arrivent plunges on October 6: FURVENT trial fails and primary endpoints not met
Bitget异动解读2026/10/06 13:35Arrivent October 6th: Major Decline Analysis
Keywords: FURVENT trial failure, primary endpoint not achieved
On October 6, 2026, ArriVent announced that the FURVENT Phase III trial did not achieve the primary endpoint of progression-free survival as assessed by a blinded independent central review. The median progression-free survival was 11.0 months in the firmonertinib 240mg group, compared to 9.5 months in the control group. The difference was not statistically significant, with a p-value of 0.0654. The company stated it is currently evaluating subsequent development strategies.
(Disclaimer: This content was generated by AI technology by collecting and summarizing public information. It is for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley: Space is the "ultimate backyard" for computing power, maintains "Overweight" rating for SpaceX (SPCX.US)
According to Odaily, Morgan Stanley has released a research report maintaining its “Overweight” rating on SpaceX (SPCX.US) and a target price of $300, representing nearly 90% upside from the closing price of $158.96 on October 2. Analyst Adam Jonas and his team put forward a bolder view: space is becoming the ultimate arena where energy is converted into intelligence in the age of AI.
The three major US stock indexes opened higher, with the Nasdaq up 0.6%.
The Dow Jones opened up 0.34%, the Nasdaq rose 0.6%, and the S&P 500 increased by 0.41%. Leading tech stocks saw gains: Super Micro Computer rose 2.58%, Nvidia was up 1.34%, and Microsoft increased by 1.24%. The Nasdaq Golden Dragon China Index edged up 0.02%, while iQIYI fell 1.94% and NetEase dropped 1.58%.
Nike drops by about 1% as Berenberg downgrades its rating to Sell
Nike (NKE.US) dropped by about 1% after Berenberg downgraded its rating to "Sell".
Crypto prices
More
